Last Price
7.23
Today's Change
+0.36 (5.24%)
Day's Change
6.86 - 7.27
Trading Volume
1,271,346
Market Cap
2 Billion
Shares Outstanding
315 Million
Avg Volume
1,536,247
Avg Price (50 Days)
6.16
Avg Price (200 Days)
3.80
PE Ratio
-45.19
EPS
-0.16
Earnings Announcement
22-Nov-2024
Previous Close
6.87
Open
7.05
Day's Range
6.86 - 7.27
Year Range
0.975 - 7.45
Trading Volume
1,271,346
1 Day Change
5.24%
5 Day Change
-0.82%
1 Month Change
29.11%
3 Month Change
39.31%
6 Month Change
158.21%
Ytd Change
244.29%
1 Year Change
588.57%
3 Year Change
416.43%
5 Year Change
382.00%
10 Year Change
382.00%
Max Change
382.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.